Elicio Therapeutics, Inc.

NASDAQ:ELTX

Biotechnology

Healthcare
$2.70 -18.90%

-$0.89 today

Market cap
$51.48M
Beta
1.14
P/E (TTM)
-1.7
EPS (TTM)
-$2.21
52W Low $2.66High $16.00

Volume 0.41M

Average 0.34M

ELTX Other Financing Activities

Financing cash flows not reported separately.

Elicio Therapeutics, Inc.NASDAQ: ELTX

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities outflow grows to $0

Q1 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $9.92M.

Context

  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.48M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$9.92M-9.8% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Financing Activities vs competitors

How ELTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.8% is the 4th highest of 8, against a peer median of -61.0%.
ELTX Competitors
Other Financing Activities for ELTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ELTXElicio Therapeutics, Inc.LTM Mar 2026$9.92M USD-9.8%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$2.74M USD+3963.4%-59.5%86.6%
ACTUActuate Therapeutics IncLTM Mar 2026$655.32K USD-61.0%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$599.2K USD+649.0%—33.6%
MOLNMolecular Partners AGLTM Mar 2026CHF 413.44K CHF-102.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$25K USD+31.6%—4.8%
PEPGPepGen Inc.LTM Mar 2026$7K USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD-100.0%——
NKTXNkarta, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding ELTX) —-61.0%-59.5%33.6%

Competitors are the stored peer set for ELTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.4M)(28.21M)(35.2M)(51.9M)(39.57M)
Depreciation & Amortization251.45K1.06M1.17M1.18M1.13M
Deferred Income Tax52.96K0000
Stock-Based Compensation617.76K579K1.18M1.45M2.7M
Change in Working Capital872.44K(150K)(57K)3.96M(3.45M)
Accounts Receivables00000
Inventory00000
Accounts Payables30.23K1.13M23K(3.33M)(366K)
Other Working Capital842.21K(1.28M)(80K)7.29M(3.08M)
Other Non-Cash Items667.05K4.54M209K8.24M2.24M
Operating Cash Flow(23.94M)(22.18M)(32.69M)(37.07M)(36.95M)
Capital Expenditures(525.36K)(654K)(66K)(87K)(16K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0034K3K0
Investing Cash Flow(525.36K)(654K)(32K)(84K)(16K)
Debt Repayment14.03M010M19.73M9.87M
Common Stock Issued101.38K82K7M5.64M26.83M
Common Stock Repurchased00(150K)00
Dividends Paid00000
Other Financing Activities314.88K82K21.76M16.96M0
Financing Cash Flow19.39M21.2M38.61M42.32M36.7M
Effect of Forex Changes3K0(68K)22K40K
Net Change in Cash(5.07M)(1.63M)5.89M5.19M(233K)
Free Cash Flow(24.46M)(22.83M)(32.76M)(37.16M)(36.97M)

Elicio Therapeutics, Inc.

NASDAQ:ELTX

Intrinsic Alpha fair value

Locked

Current Price

$2.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.